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ABSTRACT
Objective: Preventive zinc supplementation in the
form of tablets or syrup reduces the incidence of
diarrhoea and acute lower respiratory tract infections
(RTI), but its effect on malaria is inconsistent. When
zinc is administered with other micronutrients or
foods, its effect is also uncertain. We assessed the
effects of different amounts and sources of zinc on the
frequency of diarrhoea, malaria, fever and RTI in young
children.
Design, setting and populations: This community-
based, double-blind, placebo-controlled, cluster-
randomised trial of 2435 children 9 months of age was
carried out between April 2010 and July 2012 in rural
southwestern Burkina Faso.
Interventions: Participants were randomly assigned at
the concession level to receive daily 1 of 4
interventions for 9 months: (1) 20 g small-quantity
lipid-based nutrient supplement (SQ-LNS) without zinc
and placebo tablet, (2) 20 g SQ-LNS with 5 mg zinc
and placebo tablet, (3) 20 g SQ-LNS with 10 mg zinc
and placebo tablet or (4) 20 g SQ-LNS without zinc
and 5 mg zinc tablet. Participants were visited weekly
in their homes for morbidity surveillance for 9 months,
and those with uncomplicated diarrhoea and malaria
received treatment from the study field workers in the
community.
Main outcomes: Incidence and longitudinal
prevalence of diarrhoea, malaria, fever, and lower and
upper RTI by intervention group.
Results: The incidence of diarrhoea, malaria and fever
was 1.10 (±1.03 SD), 0.61 (±0.66 SD) and 1.49 (±1.12
SD) episodes per 100 child-days at risk, respectively, and
did not differ by intervention group (p=0.589, p=0.856
and p=0.830, respectively). The longitudinal prevalence
of acute lower RTI (0.1%; 95% IC 0.1–0.2%) and of
upper RTI (7.8%; 95% IC 7.1–8.4%) did not differ
among groups (p=0.234 and p=0.501, respectively).
Conclusions: Inclusion of 5 or 10 mg zinc in SQ-LNS
and provision of 5 mg zinc dispersible tablet along with
SQ-LNS had no impact on the incidence of diarrhoea,
malaria and fever or the longitudinal prevalence of RTI
compared with SQ-LNS without zinc in this population.
Trial registration number: NCT00944281.
INTRODUCTION
Undernutrition increases the risk and sever-
ity of diarrhoea and pneumonia, and
accounts for approximately 45% of all child
deaths.1 A recent systematic review identiﬁed
numerous effective interventions for redu-
cing malnutrition and child deaths, includ-
ing preventive zinc supplementation in
populations at risk of zinc deﬁciency.2
Research indicates that zinc supplementation
reduces the incidence and severity of diar-
rhoea and acute lower respiratory infections
in children,3–5 but there is less certainty
about the effects of preventive zinc supple-
mentation on other types of infections, such
Strengths and limitations of this study
▪ The strengths of the study include the double-
masked randomised design and the rigorous
quality control of the morbidity data collection
with weekly supervision and regular retraining of
the data collection team.
▪ The continuous active surveillance with a 7-day
recall period minimises the variance.
▪ For ethical reasons, we provided morbidity treat-
ment for all children, which may have altered the
cumulative morbidity that they would have other-
wise experienced and may have limited our
ability to determine how zinc would have affected
the health and morbidity of these children in the
absence of such treatment.
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as malaria. The few trials that have been conducted to
assess the impact of preventive zinc supplementation on
malaria have had contradictory results.6–10 The mechan-
ism by which zinc modulates susceptibility to infections
is uncertain, but is hypothesised to be due to its effects
on different components of the immune system.11
There is also uncertainty about the optimal way to
deliver additional zinc to children. Preventive zinc sup-
plementation has been shown to be effective when deliv-
ered alone in the form of a tablet or syrup, but not
when the supplement contained iron along with zinc.12
Moreover, when zinc is provided with foods such as com-
plementary foods or home fortiﬁcation products mixed
with foods (micronutrient powders (MNPs), lipid-based
nutrient supplements), its effect on infectious morbidity
is uncertain.13 14
Small-quantity lipid-based nutrient supplements
(SQ-LNS) are a promising home fortiﬁcation strategy to
improve the micronutrient quality of children’s diets.15–17
SQ-LNS is a dietary supplement containing peanut
paste, milk protein, essential fatty acids and a range of
vitamins and minerals. None of the three published
studies that investigated the impact of SQ-LNS on mor-
bidity found a beneﬁcial impact on diarrhoea.15 18 19
This may be due to the fact that the zinc content of
SQ-LNS was too low, the zinc was not well absorbed
and/or the studies’ sample sizes were inadequate.
In the International Lipid-based Nutrient Supplement-
Zinc (iLiNS-Zinc) study, we provided varying amounts of
zinc to children from 9 to 18 months of age via SQ-LNS
or dispersible tablets, and we assessed incidence and lon-
gitudinal prevalence of diarrhoea, malaria, fever and
respiratory tract infections during the same time period.
Our objective was to determine the optimal dose of zinc
to include in SQ-LNS for reducing infectious disease
burden. We hypothesised that young Burkinabe children
at risk of zinc deﬁciency who received either 5 or 10 mg
zinc per day in SQ-LNS provided with meals, or a 5 mg
zinc tablet per day provided between meals (positive
control) would have a decreased incidence and longitu-
dinal prevalence of diarrhoea, malaria, fever and respira-
tory tract infections compared with children who
received SQ-LNS without added zinc and a placebo tablet
(negative control). Cluster randomisation at the level of
concession (ie, extended family compound) was chosen
to reduce the risk of cross-contamination within the
family compound through food sharing.
METHODS
Study design, site and population
The morbidity results reported in the current paper are
from the iLiNS-Zinc study, a community-based, double-
blind, placebo-controlled, cluster-randomised trial that
took place between April 2010 and July 2012 in the
Dandé health district in southwestern Burkina Faso.
This region has a high prevalence of stunting (31.8%)
and underweight (19.3%) among young children,20
poor food security and holoendemic malaria transmis-
sion.21 The study design has been described in detail by
Hess et al.21a The study was registered with the US
National Institutes of Health as a clinical trial (http://
www.ClinicalTrials.gov; NCT00944281).
Randomisation
A total of 34 villages were selected for inclusion in the
study based on their accessibility during the rainy
season. Target villages were stratiﬁed by health clinic
afﬁliation, average population size, and distance from
the paved road and Bobo-Dioulasso, and assigned to the
intervention cohort or the non-intervention cohort.
Because morbidity was not assessed in the non-
intervention cohort, this paper will focus just on the
intervention cohort, which consisted of 25 villages. A
statistician from the University of California Davis, who
was blinded to the intervention groups, generated a
random allocation sequence at the level of the conces-
sion (extended family compound) using SAS V.9.3 (SAS
Institute Inc, Cary, North Carolina, USA) to assign eli-
gible children in the intervention cohort to one of four
intervention groups. Every concession had a 1/8 chance
of receiving one of the eight colour codes (two colours
for each group to reinforce the blinding). During the
trial, all participants, ﬁeld staff, study statistician and
investigators were blinded to the intervention groups.
Eligibility, enrolment and intervention
Potentially eligible children were identiﬁed by two cen-
suses at a 1-year interval (November–December 2009
and 2010) in participating communities. Children were
eligible if they were 8.80–9.99 months old, a permanent
resident of Dandé health district, and their caregivers
planned to be available during the study period and
accepted home visits for data collection. Children were
excluded when they had haemoglobin (Hb) concentra-
tion <50 g/L, weight-for-length <70% of the National
Center of Health Statistics (NCHS) reference median,22
bipedal oedema, other severe illness requiring hospital
referral, a congenital abnormality or chronic medical
condition, allergy towards peanuts or history of anaphyl-
axis or serious allergic reactions to any substance requir-
ing emergency medical care, or were concurrently
participating in any other clinical trial. Written informed
consent was obtained from one of the child’s primary
caregivers. If the caregiver was illiterate, an impartial
witness who was present during the consent process con-
ﬁrmed by co-signing that the information in the consent
document was accurately explained to the participant,
and that consent was freely given. During the enrolment
visit, length and weight were measured, as described
below. All children were screened for malaria parasites
using a rapid diagnostic test (RDT, histidine-rich protein
II; SD BIOLINE Malaria Ag P.F/Pan, Standard
Diagnostics, INC, Kyonggi-do, Korea). If the RDT was
positive, the child received antimalarial treatment
(amodiaquine-artesunate, 1 tablet/day for 3 days) and
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an antipyretic (paracetamol, 1/2 tablet × 3/day for
3 days). In case of fever with negative RDT, an antipyr-
etic was provided for 3 days. Children with reported diar-
rhoea at the time of enrolment were treated with oral
rehydration salts (ORS: 1 sachet/day for 4 days). Hb
concentration was measured by Hemocue (Hemocue
201+, HemoCue AB, Ängelholm, Sweden). Children
with Hb <80 g/L received iron supplements (ferrous
sulfate, 2–6 mg iron/kg body weight/day, depending on
anaemia severity) for 30 days and an anthelminthic
(200 mg mebendazole/day) for 3 days. After being
enrolled, participants in the intervention cohort were
assigned to receive one of four interventions from 9 to
18 months of age: (1) SQ-LNS without zinc and placebo
tablet (LNS-Zn0), (2) SQ-LNS with 5 mg zinc and
placebo tablet (LNS-Zn5), (3) SQ-LNS with 10 mg zinc
and placebo tablet (LNS-Zn10) or (4) SQ-LNS without
zinc and 5 mg zinc tablet (LNS-TabZn5). Eligible twins
were both enrolled in the study and received the same
intervention and follow-up; however, only one randomly
selected twin was included in the data analysis.
SQ-LNS, zinc and placebo tablets were produced by
Nutriset SAS (Malaunay, France). All SQ-LNS products
had the same appearance, aroma and ﬂavour, and the
zinc and placebo dispersible tablets were identical in
appearance and ﬂavour. The composition of SQ-LNS
was the same for the four intervention formulations
except for their zinc content. One sachet of 20 g
SQ-LNS provided 118 kcal, 6 mg of iron, 5 or 10 mg
added zinc for LNS-Zn5 and LNS-Zn10, respectively, and
19 other micronutrients.17 The zinc tablet provided
during this study is the same dispersible tablet provided
by UNICEF and used in programmes for diarrhoea treat-
ment in many countries, except the zinc content was
5 mg per tablet, provided as zinc sulfate. Caregivers were
instructed on how to administer the study supplements
and were advised to continue breast feeding and to feed
diverse local foods. Caregivers were also instructed to
administer 20 g SQ-LNS per day in two separate servings,
preferably mixed in a small portion of the child’s meal,
and to give the dispersible tablet once a day at least
30 min away from meals and SQ-LNS. The latter instruc-
tion was provided to optimise zinc absorption.
Supplement distribution and community-based morbidity
surveillance
From 9 to 18 months, children were visited weekly by
trained ﬁeld data collectors. During the ﬁrst part of the
study, the data collectors provided one plastic cup of
140 g of SQ-LNS and a blister package containing eight
dispersible tablets (zinc or placebo) each week. Later in
the study, the cups were replaced by seven 20 g sachets
of SQ-LNS. Adherence was assessed by obtaining infor-
mation on SQ-LNS and tablet consumption, and collect-
ing any remaining SQ-LNS and tablets and empty
packages.23
Field data collectors used a structured questionnaire
to collect a weekly morbidity history, including the
child’s general state, appetite, number of semiliquid/
liquid stools, presence of blood or mucus in stools,
vomiting, fever, signs of respiratory tract infections, and
any treatment received by the child either from study
staff members or outside the study. If the child had a
reported fever during the previous 24 h, auricular tem-
perature was measured, and an RDT and blood smear
slide were performed. As a quality control measure, aur-
icular temperature was also measured once per month
for all children independent of the caregiver’s report. In
the case of reported diarrhoea, fever with a negative
RDT and fever with a positive RDT, the child was treated
according to the Burkina Faso national guideline, as
described above. Children were referred to the nearest
health clinic for any danger signs (convulsions, lethargy
or coma, persistent vomiting or inability to eat or drink),
diarrhoea and malaria with complications, suspicion of
lower respiratory tract infection, and any other symp-
toms requiring medical attention. Field data collectors
resided in their assigned village, so that caregivers could
seek treatment for the child outside of the regularly
scheduled visit day. Field data collectors who were
approached for unscheduled evaluations followed the
same procedures outlined above.
On average, each ﬁeld data collector was assigned to
monitor 86±41 children during the entire study period.
The 25 data collectors were supervised on a weekly basis
by ﬁeld supervisors. The work of the morbidity team was
also continuously supervised by a trained nurse and two
study physicians. Field data collectors and supervisors
were retrained every 4–5 months to avoid any violation
of the study protocol.
Anthropometric, health practices and socioeconomic
status data collection
Anthropometric measurements were performed at base-
line when children were 9 months old. All measure-
ments were taken in duplicate. Weight was measured to
the nearest 0.05 kg (Seca 383, Hamburg, Germany) and
length to the nearest 0.1 cm (portable length board
Seca 417, Hamburg, Germany). In case of disagreement
between the ﬁrst two measurements (greater than 0.1 kg
for weight and 0.5 cm for length), a third measurement
was performed. The average of the two closest values
was used in the statistical analysis. Weight-for-length
z-score (WLZ), weight-for-age z-score (WAZ) and
length-for-age z-score (LAZ) were calculated using the
SAS macros for the WHO Child Growth Standards.24
Data on feeding practices and child dietary intake
were collected at baseline using a food frequency ques-
tionnaire that elicited information on consumption of
predeﬁned semisolid or solid food groups during the
previous 24 h. Variables assessing breast feeding, meal
frequency, dietary diversity and animal source food con-
sumption were constructed based on the WHO indica-
tors for assessing infant and young child feeding
practices.25
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Demographic and socioeconomic data were collected
within 2 weeks after enrolment. Data were obtained on
maternal education and marital status, Household Food
Insecurity Access Scale (HFIAS),26 number of children
under 5 years in the household, and livestock possession
and housing quality, as described in more detail by Hess
et al.27
During monthly interviews, the caregiver was asked
whether the participating child slept under a mosquito
net the night preceding the visit, and whether the child
received a high-dose vitamin A capsule during the pre-
ceding month. Photos of vitamin A supplements were
shown to the caregiver to help differentiate between
high-dose vitamin A supplements and the poliovirus oral
vaccine.
Sample size
The longitudinal prevalences of diarrhoea and malaria
were the primary outcomes. A total sample size of 2332
participants (583 per group) was needed to detect (with
a signiﬁcance of p<0.05 and power >0.80) ≥20% reduc-
tion in diarrhoea prevalence and malaria prevalence
among the four groups, assuming an attrition rate of
15%. The expected effect sizes (0.22 SDs) were based
on effects observed in previous zinc supplementation
trials.4 6 7 21 28 A total of 2435 children were enrolled in
the study and 2364 of them were included in the ﬁnal
analyses after excluding participants with less than
30 days of morbidity observations.
Statistical analysis
Morbidity definitions
Diarrhoea was deﬁned as caregiver report of three or
more liquid or semiliquid stools during a 24 h period.
An episode of diarrhoea was deﬁned as the period start-
ing the day the child ﬁrst had diarrhoea following a
diarrhoea-free period of 2 days, and ending on the last
day the child had diarrhoea that was followed by ≥2 days
without diarrhoea. The episode was considered to be
severe when associated with observed signs of dehydra-
tion, reported presence of faecal blood, reported pres-
ence of six or more liquid or semi-liquid stools in 24 h,
or when the episode lasted ≥14 days.
Fever was deﬁned as: (1) any reported fever by the
caregiver, whether or not the fever was conﬁrmed by
measured temperature during the last 24 h; or (2) any
elevated measured auricular temperature (≥37.5°C). An
episode of fever was deﬁned as the period starting the
day the child ﬁrst had fever following a fever-free period
of 2 days, and ending on the last day the child had fever
that was followed by ≥2 days without fever. The episode
of fever was considered to be unrelated to malaria (and
classiﬁed as non-malaria fever) when there was no posi-
tive RDT for any day of the episode and within 2 days of
the episode.
After enrolment, malaria was deﬁned as the presence
of reported or conﬁrmed fever during the 24 h preced-
ing the morbidity visit, associated with a positive RDT. A
malaria episode was deﬁned as the presence of a new
episode of fever and positive malaria RDT obtained
21 days after a previously treated malaria episode. An
episode of malaria was considered severe when it was
accompanied by seizures, unconsciousness or respiratory
distress (presence of wheezing/stridor or chest
in-drawing).
Acute lower respiratory illness (ALRI) was deﬁned as
any episode in which the caregiver reported cough with
respiratory difﬁculties (wheezing/stridor or chest
in-drawing). An episode of ALRI ended on the last day
the child had ALRI that was followed by at least 3 days
free of respiratory distress.
Acute upper respiratory illness (AURI) was deﬁned as
any episode in which the caregiver reported cough and
a purulent nasal discharge. An episode of AURI ended
on the last day the child had AURI that was followed by
at least 7 days free of purulent nasal discharge.
Incidence was deﬁned as the number of new episodes
of a disease per 100 days at risk and longitudinal preva-
lence as the per cent of total days of observation (or
‘recalled’ days) on which the disease was present (ie, the
numerator is the total number of days with a disease and
the denominator is the total number of days of observa-
tion). In the case of malaria, for each episode, the
21 days following the diagnosis of malaria were removed
from the total days at risk.
Data quality, cleaning and statistical analysis
All data collection forms were checked for data quality
(completeness, consistency, etc) by ﬁeld supervisors and
quality control agents. Data were double entered using
EpiData V.3.1 (EpiData Association, Odense, Denmark)
and the data sets were reviewed and validated on a
weekly basis before appending to the previous cumu-
lated database. Project coordinators routinely reviewed
the data sets for errors (eg, study identiﬁcation number,
date of visit, group assignment, inconsistent variables,
biologically implausible values and missing values) using
Stata V.11.2 (StataCorp, Texas, USA) syntaxes. Original
data collection forms were used for correction in cases
of data entry errors identiﬁed by the coordinators. A
statistical analysis plan was written by the study investiga-
tors and published to the project website (http://www.
ilins.org) prior to the start of data analysis. The investiga-
tors remained blinded until consensus on primary con-
clusions was reached. Data analyses were completed
using SAS V.9.3 (SAS Institute Inc, Cary, North Carolina,
USA).
Descriptive analysis was performed for baseline
characteristics. Weighted means were calculated by
weighting the mean number of illness days and preva-
lence by the total number of observation days, and by
weighting the mean number of episodes and incidence
rates by the total number of days at risk of a speciﬁc
illness. The incidence or prevalence in the four inter-
vention groups was compared by using binomial logistic
regression and the events/trials syntax for the response
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variable (SAS GLIMMIX procedure), controlling for
baseline characteristics and allowing for overdispersion.
The following covariates were included in the different
models: participant’s sex, baseline LAZ and WLZ (con-
tinuous), baseline Hb (continuous, only for malaria out-
comes), iron supplementation at baseline (provision or
not), and feeding practice indicators (child meets
minimum requirement or not, only for diarrhoea out-
comes); maternal education (no education, no formal
education or <1 year formal education, ≥1 year formal
education) and marital status/rank (sole wife in house-
hold, ﬁrst wife in a polygamous household, and second
wife or higher in a polygamous household), number of
children under 5 years in the household (≤1 child, 2
children and ≥3 children); household food insecurity
access score adjusted for season (season-adjusted HFIAS,
quartiles), proxy of hygiene and water quality (quar-
tiles), household livestock possession index (quartiles)
and month/year of enrolment. Continuous variables
were used when possible (normally distributed), and
were categorised according to international standards if
available (eg, WHO on infant and child feeding prac-
tices25), were constructed based on the study setting
context (eg, maternal education), or were categorised
into quartiles when other transformations were not
useful. Because randomisation was carried out at the
concession level, all analyses included random effects of
concession. Pairwise comparisons between groups were
carried out with a Tukey-Kramer adjustment to control
for overall type I error.
A set of effect modiﬁers (sex, baseline continuous
WLZ, baseline continuous and categorical (<1.5 or ≥1.5
SD29) LAZ, days at risk of illness by type of illness, mater-
nal education and marital status (categorised as above),
month/year of enrolment, seasonal adjusted HFIAS
score (quartiles), housing quality (quartiles, for diar-
rhoea only), and iron supplementation at enrolment)
were selected a priori and were assessed individually in
the models with all the covariates, by including the
potential effect modiﬁer as a main effect and in an
interaction with the intervention group variable.
Stratiﬁed analyses were performed to assess the nature
of the interaction when the interaction term was signiﬁ-
cant at the 5% level.
Final morbidity analyses included only children with at
least 30 days of morbidity observations. However, in a
sensitivity analysis, the inclusion of all available data did
not affect the results (see online supplemental table S1).
Data are presented as means±SD, unless otherwise
noted. p Values <0.05 were considered statistically
signiﬁcant.
RESULTS
A total of 3402 children were initially contacted, of
whom 3220 eligible children of consenting families were
enrolled in the study. Of these, 2435 children resided in
randomly assigned intervention communities and 785 in
non-intervention communities. The 2435 children in the
intervention cohort were randomly assigned to one of
the four intervention groups and were followed weekly
for morbidity assessment (ﬁgure 1). Caregivers of 97%
of the participating children provided information on at
least 30 days of morbidity surveillance, and 78% of the
caregivers provided information for at least 35 weeks.
The 71 children who were excluded from the ﬁnal ana-
lyses because they provided less than 30 days of morbid-
ity observations did not differ at baseline from those
included in the analysis (data not shown). There were
no differences in participation or reporting rates among
the four intervention groups.
The mean age of participants at enrolment was
9.4 months (range 8.7–10.7). More than half of the
mothers (58%) did not receive any kind of education,
and only 11% of them completed at least 1 year of
formal education. The median number of children
under 5 years per household was 2.0 (IQR=1–3) with
34% of households having at least one other child less
than 5 years of age in addition to the study participant.
The median seasonally adjusted HFIAS score was 1.50
(IQR=0.69–4.50) on a scale of 0–27, with higher score
indicating more food insecurity. The malaria RDT was
positive for ≈59% of the children at enrolment. Almost
all of the children (91%) were anaemic based on Hb
cut-off <110 g/L. Iron supplementation was provided to
26% of children at the enrolment visit, along with anti-
helminthic treatment. At baseline, ≈3% of children were
severely wasted (WLZ≤−3 SD, according to the WHO
growth standard), and ≈13% were moderately wasted
(−3 SD≤WLZ<−2 SD). Approximately 5% of children
were severely stunted (LAZ≤−3 SD) and ≈18% were
moderately stunted (−3 SD≤LAZ<−2 SD). Baseline
characteristics of the participants are shown by interven-
tion group in table 1.
The median number of observation days for all chil-
dren was 260 days (IQR=244–271). The overall daily
reported adherence for SQ-LNS and the tablets was very
high and did not differ among intervention groups.
More than 80% of children reportedly consumed the
SQ-LNS and tablets on at least 95% of the study days.
Caregivers were questioned once monthly about
whether their child slept under a mosquito net the
night before the ﬁeld worker’s visit, and the caregivers
responded positively on seven of the nine possible occa-
sions (IQR=5–8 times). Only 1.5% of caregivers (n=35)
reported that the child did not use a mosquito net at all
during the entire study period. There was no difference
in mosquito net use by intervention group. About 58%
of caregivers stated that their child received at least one
vitamin A supplement during the study period, with no
difference between groups.
The median number of days at risk for diarrhoea,
fever, malaria, and acute upper and lower respiratory
tract infections (AURI and ALRI) were 250 (IQR=230–
260), 248 (IQR=228–258), 215 (IQR=186–236), 235
(IQR=192–254) and 261 (IQR=246–270), respectively,
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and were not signiﬁcantly different among intervention
groups.
The longitudinal prevalence of diarrhoea was 3.1%
(95% CI 2.9% to 3.2%), and the incidence was 1.10
±1.03 episodes per 100 child-days which is equivalent to
4.01±3.76 episodes per child-year. Diarrhoea morbidity
did not differ by intervention group (table 2), even
when more stringent criteria were used, such as higher
stool frequency, prolonged illness or associated compli-
cations. About 17.5% of the participants did not report
any episodes of diarrhoea during the 9-month observa-
tion period. Thirty-nine per cent of children with diar-
rhoea received ORS treatment, as per the study
protocol, and there were no differences in treatment
rates by study group.
The longitudinal prevalence of malaria was 1.5%
(95% CI 1.4% to 1.6%) with children having on average
3.8±4.1 days of malaria during the study period. The
incidence of malaria was 0.61±0.66 episodes per 100
child-days (equivalent to 2.23±2.40 episodes per child-
year) and was not different among intervention groups.
Among the positive RDTs, Plasmodium falciparum was
present in 91% of cases. About 31% of the participants
did not experience any episodes of malaria during the
entire observation period. Malaria treatment was pro-
vided per study protocol to almost all children with
malaria (99.0%). The proportion of treated episodes of
malaria did not differ by group (table 2). The average
duration of malaria episodes was not statistically differ-
ent among intervention groups: 2.86, 2.99, 2.95 and
2.99 days (p=0.683), respectively, for LNS-Zn0, LNS-Zn5,
LNS-Zn10 and LNS-TabZn5. During the 9-month
follow-up period, there were only 16 cases of severe
malaria with no difference by intervention group.
The longitudinal prevalence of fever was 3.5% (95%
CI 3.4% to 3.7%). On average, participants had 8.5
±7.2 days with fever and 8% of children did not experi-
ence any days with fever. Forty-ﬁve per cent of days with
fever were associated with malaria. The incidence of
fever was 1.49±1.12 episodes per 100 child-days (equiva-
lent to 5.44±4.09 episodes per child-year) with no differ-
ence among intervention groups. The average duration
Figure 1 Flow diagram for the study participants from the initial census to the analysis of the morbidity outcomes. *Excluded
from analyses because participants provided <30 days of morbidity surveillance. LNS-Zn0, SQ-LNS without zinc and placebo
tablet; LNS-Zn5, SQ-LNS with 5 mg zinc and placebo tablet; LNS-Zn10, SQ-LNS with 10 mg zinc and placebo tablet;
LNS-TabZn5, SQ-LNS without zinc and 5 mg zinc tablet; NI, non-intervention.
6 Somé JW, et al. BMJ Open 2015;5:e007828. doi:10.1136/bmjopen-2015-007828
Open Access
group.bmj.com on February 1, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
of the episodes of fever was not statistically different by
groups: 2.47, 2.50, 2.49 and 2.53 days (p=0.733), respect-
ively, for LNS-Zn0, LNS-Zn5, LNS-Zn10 and
LNS-TabZn5. Fever treatment was provided for 72.3% of
fever episodes, and the proportion of treated episodes
of fever did not differ among groups. The longitudinal
prevalence and incidence of non-malaria fever were
2.02% (95% CI 1.92% to 2.12%) and 0.95±0.99 episodes
per 100 child-days, respectively, and were not different
by intervention group (table 2).
The mean number of days with AURI and ALRI were
19.6±32.3 and 0.3±3.2, respectively. Almost 36% of chil-
dren (n=847) had no episodes of AURI reported and
97% (n=2284) had no episodes of ALRI. The longitu-
dinal prevalence for AURI was 7.8% (95% CI 7.1% to
8.4%) and for ALRI 0.1% (95% CI 0.1% to 0.2%). There
were no differences in any of the respiratory morbidity
indicators by intervention group (table 2).
There were no signiﬁcant interactions between zinc
intervention group and the different predetermined
effect modiﬁers for the incidence of diarrhoea, malaria
or fever.
Seventy severe adverse events (SAEs), deﬁned as hospi-
talisations or deaths, occurred during the 9-month
follow-up period. These SAEs did not differ signiﬁcantly
by intervention group (p=0.497). Of the 2435 children
enrolled in the intervention cohort, 33 died during the
follow-up period: 9 (1.50%), 2 (0.33%), 10 (1.66%) and
12 (1.94%) participants in the LNS-Zn0, LNS-Zn5,
LNS-Zn10 and LNS-TabZn5, respectively. The main sus-
pected causes of death were severe malaria, gastroenter-
itis and respiratory infections.
DISCUSSION
The present dose–response trial aimed to determine the
optimal amount of zinc to include in SQ-LNS for the
prevention of common childhood infections. We found
no impact of adding either 5 or 10 mg zinc to the daily
portion of SQ-LNS, or of providing 5 mg zinc/day as a
Table 1 Baseline characteristics of study participants by intervention group
LNS-Zn0 LNS-Zn5 LNS-Zn10 LNS-TabZn5
N 602 613 603 617
Child characteristics
Sex (% male) 50.7 48.8 53.1 49.3
Mean age (month) 9.4±0.3 9.4±0.4 9.4±0.3 9.4±0.4
Mean LAZ −1.21±1.07 −1.20±1.11 −1.32±1.07 −1.12±1.10
Mean WLZ −0.96±1.06 −0.95±1.08 −1.09±0.99 −0.89±1.06
% (n) Stunting (LAZ <−2 SD)* 23.1 (139) 22.1 (135) 26.2 (158) 20.2 (124)
% (n) Wasting (WLZ <−2 SD)* 16.6 (100) 15.4 (94) 18.4 (111) 14.3 (88)
% (n) Underweight (WAZ <−2 SD)* 26.6 (160) 29.4 (180) 34.0 (205) 26.4 (163)
% RDT positive 61.3 58.4 61.0 56. 9
Mean haemoglobin (g/L) 90±15 90±16 89±15 90±15
% iron supplementation 24.7 25.3 26.5 26.4
% (n)≥Minimum meal frequency in previous 24 h†‡ 35.8 (215) 33.8 (207) 36.3 (219) 32.9 (203)
% (n)≥Minimum dietary diversity in previous 24 h§ 10.0 (60) 12.6 (77) 13.1 (79) 12.8 (79)
% (n)≥1 animal source food in previous 24 h¶ 21.5 (129) 24.1 (148) 22.2 (134) 23.3 (144)
Maternal characteristics
Per cent of mothers with no education 60.8 56.2 56.3 57.7
Per cent of sole wife of household 57.5 50.1 57.1 60.8
Household characteristics (N) 552 555 549 559
Median of number children ≤5 years 2.0 (IQR=1–3) 2.0 (IQR=1–3) 2.0 (IQR=1–2) 2.0 (IQR=1–2)
Median seasonally adjusted HFIAS score 1.50
(IQR=0.69–4.69)
1.50
(IQR=0.69–4.69)
1.50
(IQR=0.69–4.80)
1.50
(IQR=0.69–3.80)
Housing quality index −0.01±1.00 0.11±0.99 −0.03 2±0.98 0.10±1.04
Livestock index (TLU) 4.76±7.81 4.78±8.09 4.46±6.59 4.89±12.72
Results shown are mean±SD or percentage and median with IQR.
Housing quality index constructed based on following characteristics: drinking water supply, sanitation facilities, wall material, flooring material
and roofing material, which were combined into an asset using (with a mean of zero and a SD of one) principal component analysis.
*WHO Child Growth Standards.24
†Minimum meal frequency during the previous 24 h is 3 meals/snacks if the child is still breast fed or 4 meals/snacks if the child is not breast
fed.25
‡The collection of the variable started after the beginning of the study, therefore information on 195 participants is missing.
§Minimum food group diversity during the previous 24 h is consumption of four or more food groups out of seven.25
¶Consumption of one or more animal source food during the previous 24 h.
HFIAS, Household Food Insecurity Access Scale; LAZ, length-for-age z-score; LNS-Zn0, SQ-LNS without zinc and placebo tablet; LNS-Zn5,
SQ-LNS with 5 mg zinc and placebo tablet; LNS-Zn10, SQ-LNS with 10 mg zinc and placebo tablet; LNS-TabZn5, SQ-LNS without zinc and
5 mg zinc tablet; SQ-LNS, small-quantity lipid-based nutrient supplement; RDT, rapid diagnostic test; TLU, tropical livestock unit;
WAZ, weight-for-age z-score; WLZ, weight-for-length z-score.
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Table 2 Number of episodes, incidence and longitudinal prevalence of diarrhoea, fever, malaria and respiratory tract infections in young children during 9 months of observation
by intervention group*
LNS-Zn0 n=579 LNS-Zn5 n=593 LNS-Zn10 n=593 LNS-TabZn5 n=599 p Value† p Value‡
Total number of child-days for diarrhoea 134 827 136 531 136 630 138 275
Number of episodes of diarrhea§ 2.61±2.27 2.67±2.27 2.51±2.15 2.52±2.26 0.473 0.587
Incidence of diarrhoea (episodes/100 child-days at risk)§ 1.11±1.05 1.14±1.05 1.06±0.98 1.08±1.02 0.580 0.589
Number of episodes of severe diarrhoea§ 0.55±0.94 0.64±1.01 0.61±0.96 0.57±0.96 0.742 0.509
Incidence of severe diarrhoea (episodes/100 child-days at risk)§ 0.24±0.42 0.27±0.46 0.26±0.41 0.25±0.45 0.744 0.511
Number of diarrhoea episodes treated with ORS§ 0.97±1.12 0.96±1.22 0.98±1.16 0.90±1.17 0.611 0.723
Per cent of diarrhoea episodes treated with ORS§ 39.7 (36.4 to 42.9) 36.4 (33.4 to 39.5) 41.3 (38.0 to 44.6) 37.6 (34.3 to 40.8) 0.355 0.418
Total number of child-days for fever 133 715 135 490 135 198 137 012
Number of episodes of fever¶ 3.57±2.46 3.44±2.54 3.49±2.43 3.42±2.30 0.472 0.728
Incidence of fever (episodes/100 child-days at risk)¶ 1.53±1.16 1.48±1.19 1.48±1.10 1.46±1.04 0.787 0.830
Number episodes of fever treated with antipyretic and/or antimalaria¶ 2.38±1.71 2.34±1.76 2.49±1.81 2.34±1.74 0.397 0.638
Per cent of fever episodes treated with antipyretic and/or antimalaria¶ 70.9 (68.3 to 73.5) 71.8 (69.2 to 74.4) 74.3 (71.9 to 76.7) 72.1 (69.5 to 74.6) 0.063 0.091
Incidence of non-malaria fever (episodes/100 child-days at risk)¶ 0.97±1.05 0.93±1.03 0.95±0.95 0.94±0.93 0.883 0.920
Longitudinal prevalence of non-malaria fever¶ 2.06 (1.86 to 2.27) 1.96 (1.76 to 2.15) 2.05 (1.85 to 2.25) 2.00 (1.81 to 2.19) 0.814 0.713
Total number of child-days for malaria 117 513 119 467 119 156 121 395
Number of malaria episodes** 1.32±1.14 1.30±1.19 1.27±1.10 1.24±1.12 0.615 0.872
Incidence of malaria (episodes/100 child-days at risk)** 0.63±0.65 0.62±0.70 0.61±0.63 0.59±0.65 0.762 0.856
Number of episodes of malaria treated with antimalaria** 1.31±1.13 1.29±1.19 1.26±1.09 1.21±1.11 0.544 0.803
Per cent of malaria episodes treated with antimalaria** 99.2 (98.5 to 99.9) 99.1 (98.4 to 99.9) 99.4 (98.9 to 99.8) 98.3 (97.2 to 99.4) 0.518 0.430
Number of days with AURI†† 19.1±32.6 18.6±30.3 20.3±32.0 20.3±34.2 0.873 0.695
Longitudinal prevalence of AURI†† 7.5 (6.3 to 8.7) 7.3 (6.2 to 8.4) 8.1 (6.9 to 9.3) 8.1 (6.7 to 9.4) 0.658 0.501
Number of days with ALRI†† 0.3±2.4 0.5±4.9 0.3±2.1 0.3±2.3 0.650 0.451
Longitudinal prevalence of ALRI†† 0.12 (0.01 to 0.23) 0.19 (0.03 to 0.34) 0.12 (0.04 to 0.19) 0.10 (0.03 to 0.18) 0.606 0.234
*Values are mean±SD for number of episodes, number of days of illness and incidence (episodes per 100 child-days at risk), and percentage (95% CI) for longitudinal prevalence. Values of
incidence and longitudinal prevalence are weighted by the number of days at risk and number of days of observation, respectively. Incidence and longitudinal prevalence were compared by
intervention group using binomial logistic regression. Linear mixed model was used for the group-wise comparisons of number of episodes and number of days of illness.
†Unadjusted p value (models allowed for overdispersion and included random effect of concession except for comparison of percentage of treated episodes in which models did not include
effect of concession).
‡Adjusted p value (models included a set of covariates, and the random effect of concession and allowed for overdispersion).
§For diarrhoea, group-wise comparisons were performed controlling for child sex, baseline LAZ and WLZ, month and year of enrolment, number of days at risk of diarrhoea, maternal education
and marital status, seasonally adjusted HFIAS score, housing quality index, livestock index, minimum meal frequency, minimum food group diversity and consumption of animal source foods at
9 months.
¶For fever, group-wise comparisons were performed controlling for child sex, baseline LAZ and WLZ, month and year of enrolment, number of days at risk of fever, maternal education and
marital status, seasonally adjusted HFIAS score and iron supplementation.
**For malaria, group-wise comparisons were performed controlling for child sex, baseline LAZ and WLZ, baseline haemoglobin, month and year of enrolment, number of days at risk of malaria,
maternal education and marital status and seasonally adjusted HFIAS score.
††For respiratory tract infections, group-wise comparisons were performed controlling for child sex, baseline LAZ and WLZ, month and year of enrolment, number of days of observation,
maternal education and marital status, seasonally adjusted HFIAS score and iron supplementation.
AURI, acute upper respiratory illness; ALRI, acute lower respiratory illness; HFIAS, Household Food Insecurity Access Scale; LAZ, length-for-age z-score; LNS-Zn0, SQ-LNS without zinc and
placebo tablet; LNS-Zn5, SQ-LNS with 5 mg zinc and placebo tablet; LNS-Zn10, SQ-LNS with 10 mg zinc and placebo tablet; LNS-TabZn5, SQ-LNS without zinc and 5 mg zinc tablet; ORS,
oral rehydration salts; SQ-LNS, small-quantity lipid-based nutrient supplement; WLZ, weight-for-length z-score.
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dispersible tablet on the incidence, longitudinal preva-
lence or duration of diarrhoea, malaria, fever or respira-
tory tract infections in children 9–18 months of age,
compared with SQ-LNS without zinc. These results
differ from the ﬁndings of previous community-based
trials of preventive zinc supplementation. In particular,
three meta-analyses of preventive zinc supplementation,
in which zinc was given in form of a tablet or syrup,
reported that diarrhoea incidence was reduced by 13–
20%, and acute lower respiratory tract infection inci-
dence was reduced by 8–19%, compared with a control
group.4 5 30
Possible explanations for the lack of any observed
effects of zinc on morbidity outcomes in the present
study are: (1) the population was not zinc deﬁcient, (2)
the supplemental zinc was poorly absorbed or utilised,
(3) the supplements were not consumed in sufﬁcient
amounts or (4) other components of the supplement
interfered with the beneﬁcial effects of zinc.
With regard to the ﬁrst possibility, we have previously
reported that 35.2% of the children had initial plasma
zinc concentrations <65 mg/L,27 and there was a high
prevalence of stunting, so the study population does,
indeed, seem to have a high risk of zinc deﬁciency.
It is well known that zinc absorption from cereal-based
diets is substantially less than from dispersible tablets or
liquid supplements, in part due to the phytate content
of the mixed diets.31 32 Although the phytate content of
the SQ-LNS used in the present study is very low
(phytate:zinc molar ratio <1),17 33 the phytate:zinc ratio
may be higher when SQ-LNS is mixed with foods. In the
study site, complementary foods for infants and young
children are mainly cereal-based, so this may have
reduced zinc uptake. However, we have previously found
that adding zinc fortiﬁcants to cereal-based diets
increases net zinc absorption,34 35 so there should have
been progressively greater zinc uptake when higher
amounts were added to SQ-LNS. If this had occurred,
we would have expected to see the strongest protective
effect in the LNS-Zn10 group. Additionally, in a sub-
group of participants (n=192) at 11 and 16 months of
age, SQ-LNS was observed given alone (as a snack) in
60% and 86% of the observed servings, respectively, so
possible interference of the diet with zinc uptake would
be less likely in these cases.23
Another possibility is that the postabsorptive metabol-
ism of zinc differs when it is provided with food rather
than as a supplement given between meals. For
example, previous studies have found that providing
zinc in food produces a lower response in plasma zinc
concentration than when additional zinc is provided as
a supplement.36–38 However, in the present study, we
also failed to detect a signiﬁcant rise in plasma zinc
concentration in the positive control group that
received additional zinc in the form of a dispersible
tablet, which has been previously shown to have a sub-
stantial impact on plasma zinc concentration when
administration was directly observed in a very similar
study population in neighbouring communities in
Burkina Faso.39 This suggests that adherence to the
study supplements might have been insufﬁcient to
produce a functional response in zinc status in the
present study, despite the high reported adherence rate,
as described previously.23
One recent meta-analysis of the effect of preventive
zinc supplementation concluded that the beneﬁcial
effects of supplemental zinc for reducing diarrhoea inci-
dence were not detectable when zinc was provided along
with iron.12 The SQ-LNS used in the present study con-
tained 6 mg iron. Because all of the study groups
received SQ-LNS containing iron, we cannot rule out
the possibility that iron in the SQ-LNS undermined a
potentially beneﬁcial effect of zinc on diarrhoea. The
current study results are similar to a recent report from
Haiti, where providing 4 mg zinc daily in 20 g LNS to
infants aged 6–11 months for 3 or 6 months had no
effect on diarrhoea, respiratory infections and other
morbidity outcomes, compared with a non-
supplemented control group.18 Similarly, a previous
study in Peru found no effect of adding 3 mg zinc/day
to a cereal porridge on diarrhoea, fever, and upper and
lower respiratory infections in young children.36
Evidence for a preventive effect of zinc supplementa-
tion on malaria incidence is inconsistent. Only one
study conducted in Papua New Guinea, using a 10 mg
zinc tablet to supplement children aged 6–60 months,
found a signiﬁcant 38% reduction in microscopy-
conﬁrmed malaria-related visits to a health facility.9 A
second study carried out earlier in the Gambia, in which
children aged 0.6–2.3 years received a beverage fortiﬁed
with 70 mg zinc or a placebo beverage twice weekly,
found a trend towards fewer malaria episodes based on
health clinic records.6 Both studies reported a reduction
in severe malaria episodes requiring a visit to a health
facility. In the present study, we hypothesised that the
weekly home visits to diagnose and treat malaria may
have prevented severe malaria episodes requiring a visit
to a health centre and possibly hospitalisation. A rela-
tively recent study that was completed in Burkina Faso,
providing both zinc and high-dose vitamin A supple-
ments, found a 30% reduction in malaria episodes
among children 6–72 months of age, but it was not pos-
sible to attribute this effect speciﬁcally to zinc.21 In con-
trast, three other studies did not show any effect of zinc
supplementation on malaria, similar to our study. Two of
the latter studies, implemented in Burkina Faso and
Peru, and using community-based assessment of malaria,
found no effect of supplemental zinc, alone or in com-
bination with iron, on malaria compared with no zinc.7 8
The third study by Veenemans et al10 assessed malaria
through health clinic visits and did not ﬁnd that the sup-
plementation of zinc alone, or multinutrients with or
without zinc, affected clinic-based conﬁrmed malaria
incidence in Tanzanian children aged 6–60 months com-
pared with placebo. They also reported no effect on
severe malaria episodes.
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Recent studies of iron supplements and iron-
containing MNPs found an increased incidence of diar-
rhoea and respiratory infections.40–42 We could not
assess the effect of iron in the present study because all
intervention groups received iron-containing SQ-LNS.
There was no evidence to suggest that the addition of 5
or 10 mg zinc to SQ-LNS produced adverse effects.
There was no increase in the incidence, prevalence or
duration of any of the diseases of interest in the
LNS-Zn5 or LNS-Zn10 groups compared with the nega-
tive and positive control groups. However, the study was
not powered to detect a potential difference in hospital-
isation and mortality rates among intervention groups.
Notably, the death rate was signiﬁcantly lower for the
intervention cohort (ie, the combined 4 intervention
groups) compared with the non-intervention cohort.27
Several strengths of the current study are noteworthy.
The morbidity surveillance was rigorously supervised,
data collection forms were reviewed weekly and the data
collection team was included in frequent refresher train-
ing. The data were double entered and edited methodic-
ally. Although more frequent morbidity surveillance
(eg, 2–3 days recall) might have been preferable to min-
imise possible recall bias,43 44 a recent analysis of mor-
bidity surveillance found that a 7-day recall period had
little bias with regard to comparing incidence rates
among speciﬁc risk groups, and the mean square error
was minimised with a recall period of approximately
7 days.45 Another possible limitation of the study is the
fact that we provided treatment for all children in the
intervention cohort who were reported to have diar-
rhoea, fever or conﬁrmed malaria, which may have
reduced our ability to determine how zinc would have
affected the children’s risk of morbidity in the absence
of such treatment. Moreover, it is conceivable that the
presence of other nutrients in LNS reduced the ability
to detect a speciﬁc additive effect of supplemental zinc.
CONCLUSION
Supplementation with 5 or 10 mg zinc added to SQ-LNS
or with a 5 mg dispersible zinc tablet did not affect the
incidence, longitudinal prevalence or duration of diar-
rhoea, fever, malaria and respiratory tract infection in
Burkinabe children aged 9–18 months compared with
children receiving SQ-LNS without any added zinc.
Inadequate zinc absorption from SQ-LNS and insufﬁ-
cient adherence to the dispersible tablets are possible
explanations for the absence of any detectable effects of
additional zinc in the study population. SQ-LNS absorp-
tion studies are needed to evaluate the quantity of
absorbed zinc when a child consumes SQ-LNS. Based on
the results of the present study, it is not possible to deter-
mine the optimal amount of zinc to add to SQ-LNS, so
current WHO guidelines on the zinc content of home
fortiﬁcation products for children should remain in
effect until additional data become available from other
dose–response trials.
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